Agios Q2 2025 net loss $112M; PYRUKYND revenue $12.5M; PDUFA Sept 7 for thalassemia

AGIOS PHARMACEUTICALS, INC.

2025-Q2 EPS reported -$3.49 revenue$21,181,000

Net loss $112.0M vs $96.1M YoY; PYRUKYND net revenue $12.5M, up from $8.6M in Q2 2024.
Cash and marketable securities $1.3B; expects to fund potential thalassemia and SCD launches.
FDA PDUFA goal date for PYRUKYND sNDA in thalassemia is Sept 7, 2025; launch prep underway.
RISE UP Phase 3 topline for mitapivat in sickle cell disease on track by year-end 2025.
Dosed first patient in tebapivat Phase 2 for SCD; IND clearance for AG-236 siRNA for PV.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.